类器官培养板

细胞培养板，用于简便且可重复的生成类器官

率先评论此产品

产品号 #（选择产品）

产品号 #200-0561_C

细胞培养板，用于简便且可重复生成类器官

产品优势

减少类器官大小和生长的差异，以提高一致性和可重复性
消除死区，控制基质深度，确保类器官的稳定均一生长和成熟
提高图像分辨率，实现更清晰，更准确的显微分析
减少边缘效应，不需要板预热，提高实验效率
支持高通量筛选和自动化流程，适用于大规模研究

产品组分包括

减少类器官大小和生长的差异，提高一致性和可重复性消除死区并控制基质深度，确保类器官的稳定均一生长和成熟提升图像分辨率，实现更清晰、更精准的显微分析降低边缘效应并免预热培养板，从而提高实验效率支持高通量筛选和自动化流程，适用于大规模研究

跳到结尾的图片库

跳转到图像库的开头

总览

使用类器官培养板可简化类器官研究流程，解决传统基质包埋培养中常见的类器官培养挑战，例如差异性大、增长不一致等问题。该板旨在增强一致性，确保均匀的基质厚度，减少半月板效应，从而实现更轻松快速的接种、更清晰的成像，以及更可靠的实验结果。类器官将以更可预测的方式生长，帮助您更高效地工作，并增强对数据的信心。
优化的孔设计减少了边缘效应，并免去预热步骤，节省时间，并确保每个孔都可用，从而提高了每次实验的表现。与康宁®Matrigel®和其他矩阵以及自动化系统兼容，该板完全适合高通量工作流程，使其成为药物筛选或疾病建模等大规模研究的理想解决方案。在大小、形状、生长和成熟方面一致的类器官，有助于构建更具生理相关性的模型，更真实地模拟体内环境，适用于研究复杂疾病机制、测试治疗反应和推进大规模体外建模的理想选择。

类器官培养板适用于大多数传统包埋于基质穹顶中的类器官培养流程，包括使用Interticult™类器官生长培养基（人）和Interticult™类器官分化培养基（人）培养肠类器官，或使用Hepatcult™类器官生长培养基（人）和Hepatcult™类器官分化培养基（人）培养肝类器官。.培养的肝类器官。

实验数据

Figure 1. Organoid Culture Plates Enable Superior Imaging and Ease of Use Over Dome Culture in Standard Culture Plates

(A,B) Challenges associated with organoids cultured in matrix domes using standard culture plates include inconsistencies by manually placing domes in the center of the well, culture “dead zones” with poor or no growth, variability in dome shape, height, and position, the inability to form domes from diluted matrix, and imaging impairment due to the meniscus. (C,D) The stepped features of the Organoid Culture Plates support a standardized matrix depth, reduced meniscus, and increased culture robustness resulting in more uniform growth, uniform organoid position, and fewer failed wells. Additionally, an optional second matrix volume enables layered cultures or co-cultures. Taken together, Organoid Culture Plates enable increased user efficacy, as well as clearer imaging for more accurate observations to benefit detailed studies and both quantitative and qualitative data collection.

Organoid Culture Plates Support Equivalent Intestinal Cell Growth in Addition to Enhanced Imaging

Figure 2. Organoid Culture Plates Support Equivalent Cell Growth in Addition to Enhanced Imaging

Organoid morphology and growth in the Organoid Culture Plates were assessed against dome culture in standard culture plates in both (A,B,C) 96- and (D,E,F) 24-well plate formats. Brightfield images show expected cystic morphology in human intestinal organoids cultured in the (A) 96-well Organoid Culture Plate and (B) 96-well standard culture plate after 7 days. (C) Human intestinal organoid growth was assessed in the 96-well Organoid Culture Plates or standard culture plates over 5 passages. The cell number was normalized to the number of fragments at Day 0 to account for different seeding volumes between the 96-well Organoid Culture Plates and the 96-well standard culture plates. The Organoid Culture Plates had a significantly higher normalized cell number at passage 2 but were otherwise equivalent in their capacity to support cellular growth when compared to standard culture plates (n = 3). Brightfield images show expected cystic morphology in human intestinal organoids culture in the (D) 24-well Organoid Culture Plate and (E) 24-well standard standard culture plates after 7 days. (F) Human intestinal organoid growth was assessed in the 24-well Organoid Culture Plates or in standard culture plates over 5 passages, demonstrating equivalent capacity to support cellular growth between culture plates (n = 3), ** p < 0.01 Significance determined using a mixed-effects analysis with Sidak’s test for multiple comparisons.

Figure 3. Organoid Culture Plates Enhance Consistency in Toxicity Screening by Providing a Standardized Platform

Human-derived intestinal organoids were cultured in 96-well Organoid Culture Plates or 96-well standard culture plates for 2 days, followed by Gefitinib treatment for an additional 4 days. Relative cell viability was assessed on Day 6 via CellTiterGloⓇ 3D analysis. (A) Screening cultures in Organoid Culture Plates produced similar IC50 values to organoid domes in standard culture plates after Gefitinib treatment (0.797 ± 0.145 µM and 0.667 ± 0.152 µM respectively). (B) Organoids cultured in the Organoid Culture Plates had a lower coefficient of variation in cell viability between technical replicates following the Gefitinib treatment compared to the dome cultures from the standard culture plates, resulting in higher confidence and more robust data. %CV = Percent coefficient of variation. OCP = Organoid Culture Plate. SCP = Standard Culture Plate. %CV reduction was calculated using 1 - %CV Organoid Culture Plate / %CV Standard Culture Plate

Figure 4. Organoid Culture Plates Reduce Intra-Well and Inter-Well Heterogeneity for Increased Consistency in Organoid Size

(A) Within a single well, human intestinal organoids cultured in the 96-well Organoid Culture Plates have a reduced range of organoid cross-sectional area when compared to human intestinal organoids cultured in standard culture plates. (B) For inter-well comparisons, organoids cultured in the Organoid Culture Plates exhibited lower variability in cross-sectional area compared to the organoid cultured in standard culture plates, as indicated by the reduced spread of the data. (C) The coefficient of variation (%CV) was used to measure consistency and reproducibility in the inter-well organoid cross-sectional area between culture plate formats, demonstrating reduced inter-well organoid size for organoids cultured in the Organoid Culture Plates. %CV reduction was calculated using 1 - %CV Organoid Culture Plate/%CV Standard Culture Plate

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。

Document Type

Product Name

Catalog #

Lot #

Language

Document Type

Product Information Sheet

Product Name

Organoid Culture Plates, 96 wells

Catalog #